Author: ["Risto Kerkelä","Luanda Grazette","Rinat Yacobi","Cezar Iliescu","Richard Patten","Cara Beahm","Brian Walters","Sergei Shevtsov","Stéphanie Pesant","Fred J Clubb","Anthony Rosenzweig","Robert N Salomon","Richard A Van Etten","Joseph Alroy","Jean-Bernard Durand","Thomas Force"]
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Imatinib mesylate (Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia. Here we report ten individuals who developed severe congestive heart failure while on imatinib and we show that imatinib-treated mice develop left ventricular contractile dysfunction. Transmission electron micrographs from humans and mice treated with imatinib show mitochondrial abnormalities and accumulation of membrane whorls in both vacuoles and the sarco- (endo-) plasmic reticulum, findings suggestive of a toxic myopathy. With imatinib treatment, cardiomyocytes in culture show activation of the endoplasmic reticulum (ER) stress response, collapse of the mitochondrial membrane potential, release of cytochrome c into the cytosol, reduction in cellular ATP content and cell death. Retroviral gene transfer of an imatinib-resistant mutant of c-Abl, alleviation of ER stress or inhibition of Jun amino-terminal kinases, which are activated as a consequence of ER stress, largely rescues cardiomyocytes from imatinib-induced death. Thus, cardiotoxicity is an unanticipated side effect of inhibition of c-Abl by imatinib.Cite this article
Kerkelä, R., Grazette, L., Yacobi, R. et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12, 908–916 (2006). https://doi.org/10.1038/nm1446 